Matrix Pharmacorp
Matrix Pharmacorp is a peptide manufacturer based in India (Hyderabad). Direct manufacturer. Holds US DMFs for abaloparatide, icatibant, leuprolide, octreotide and 2 more API.
Listing reviewed October 2026.
About Matrix Pharmacorp
Hyderabad-based API manufacturer, formerly the API business of Viatris (Mylan) and independent again since Viatris sold it in 2024. Holds active US Drug Master Files for abaloparatide, icatibant, leuprolide, octreotide, plecanatide and sincalide API. FDA warning letters to its Vizianagaram (2019) and Hyderabad (2020) sites were followed by re-inspections classed NAI (2023) and VAI (2022, 2025).
Directory assessment: Matrix Pharmacorp is listed as a manufacturer in the peptide supply chain, serving Asia markets from India (Hyderabad). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 3 sources for reference. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.
- Abaloparatide: DMF 36475 (Type II, active), submitted 2021-12-03
- Icatibant: DMF 31260 (Type II, active), submitted 2016-12-29
- Leuprolide: DMF 32295 (Type II, active), submitted 2017-12-19
- Octreotide: DMF 27729 (Type II, active), submitted 2013-12-20
- Plecanatide: DMF 34227 (Type II, active), submitted 2019-11-27
- Sincalide: DMF 32302 (Type II, active), submitted 2018-01-07
DMF numbers from the FDA quarterly DMF list. A filed DMF is not FDA approval; its contents are confidential. Reviewed 2026-10-23.